This site uses cookies to store information on your computer. Learn more x

Consensus Figures

A number of international financial analysts cover DSM. The most recent consensus figures – provided by Vara Research – are detailed below. The figures are based on the estimates given by the banks that were approached by Vara Research.

Analysts' consensus Q3 2018 and FY 2018 as at 12 October 2018

  Q3 2017 Q4 2017 FY 2017 Q3 2018 E FY 2018 E
Total Sales          
  Number of Estimates       17 17
  Highest       2,330 9,379
  Consensus 2,136 2,176 8,632 2,222 9,260
  Median       2,227 9,275
  Lowest       2,151 9,029
Total adjusted EBITDA          
  Number of Estimates       17 17
  Highest       403 1,847
  Consensus 365 359 1,445 390 1,813
  Median       391 1,807
  Lowest       370 1,788
of which adj. EBITDA from"Temporary Vitamin Effect"          
  Number of Estimates       9 9
  Highest       19 294
  Consensus - - - 8 281
  Median       10 285
           
Total adjusted EBIT          
  Number of Estimates       16 17
  Highest       282 1,381
  Consensus 239 240 957 271 1,327
  Median       272 1,337
  Lowest       258 1,095
Nutrition, Sales          
  Number of Estimates       17 17
  Highest       1,521 6,190
  Consensus 1,373 1,428 5,579 1,427 6,084
  Median       1,435 6,077
  Lowest       1,366 5,825
Nutrition, Total adj. EBITDA          
  Number of Estimates       17 17
  Highest       300 1,423
  Consensus 258 267 1,053 282 1,396
  Median       283 1,392
  Lowest       261 1,372
of which adj. EBITDA from"Temporary Vitamin Effect"          
  Number of Estimates       9 9
  Highest       19 294
  Consensus - - - 8 281
  Median       10 285
  Lowest       0 260
Nutrition, adj. EBIT          
  Number of Estimates       16 16
  Highest       228 1,139
  Consensus 192 195 770 212 1,112
  Median       212 1,112
  Lowest       193 1,082
Materials, Sales          
  Number of Estimates       17 17
  Highest       755 2,986
  Consensus 706 693 2,825 737 2,954
  Median       736 2,952
  Lowest       713 2,912
Materials, adj. EBITDA          
  Number of Estimates       17 17
  Highest       136 527
  Consensus 128 119 488 131 516
  Median       131 517
  Lowest       123 499
Materials, adj. EBIT          
  Number of Estimates       16 16
  Highest       105 402
  Consensus 98 86 361 99 389
  Median       100 389
  Lowest       89 368
Innovation Center, Sales          
  Number of Estimates       17 17
  Highest       49 186
  Consensus 42 43 169 43 167
  Median       43 163
  Lowest       38 152
Innovation Center, adj. EBITDA          
  Number of Estimates       17 17
  Highest       6 12
  Consensus 4 4 9 3 7
  Median       3 8
  Lowest       0 0
Innovation Center, adj. EBIT          
  Number of Estimates       16 16
  Highest       -2 -16
  Consensus -17 -1 -30 -5 -20
  Median       -4 -19
  Lowest       -9 -28
Corporate Activities, Sales          
  Number of Estimates       17 17
  Highest       20 63
  Consensus 15 12 59 15 55
  Median       15 55
  Lowest       11 46
Corporate Activities, adj. EBITDA          
  Number of Estimates       17 17
  Highest       -22 -98
  Consensus -25 -31 -105 -26 -106
  Median       -26 -105
  Lowest       -30 -110
Corporate Activities, adj. EBIT          
  Number of Estimates       16 16
  Highest       -33 -134
  Consensus -34 -40 -144 -35 -140
  Median       -35 -140
  Lowest       -38 -147
Profit for the period, before exceptional items - Cont. Ops.          
  Number of Estimates       15 16
  Highest       215 1,058
  Consensus 166 202 706 203 1,024
  Median       203 1,028
  Lowest       193 972
Net EPS before exceptional items - Cont. Ops.          
  Number of Estimates       15 16
  Highest       1.21 5.98
  Consensus 0.91 1.11 3.92 1.14 5.80
  Median       1.15 5.83
  Lowest       1.06 5.56

Disclaimer
Consensus earnings estimates are based on earnings projections made by securities analysts who cover DSM. Any opinions, forecasts, estimates, projections or predictions regarding DSM’s performance made by the analysts (and, therefore, the Consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of DSM or its management. DSM does not by providing these estimates imply its endorsement of or concurrence with such information, conclusions or recommendations. DSM assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.